CRBP · Corbus Pharmaceuticals Holdings, Inc.

$10.09 +0.01 (+0.10%) At close · Aug 14

Market Cap

$195.15M

19.34M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Yuval Cohen	Chief Executive Officer	$646,566	$373,682	$666,699	$2,039,294	—	$23,884	$3,750,125
Dominic Smethurst	Chief Medical Officer	$519,313	$168,078	$266,288	$812,866	—	$33,597	$1,800,142
Sean Moran	Chief Financial Officer	$481,137	$185,382	$269,225	$824,453	—	$29,226	$1,789,423

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Yuval Cohen	Chief Executive Officer	$621,883	$380,868	$1,700,781	$1,518,871	—	$23,035	$4,245,438
Dominic Smethurst	Chief Medical Officer	$408,914	—	$1,303,500	$1,165,650	—	$14,908	$2,892,972
Sean Moran	Chief Financial Officer	$462,769	$188,947	$924,048	$825,215	—	$28,526	$2,429,505

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Yuval Cohen	Chief Executive Officer	$598,850	$283,855	—	$229,842	—	$25,075	$1,137,622
Rachael Brake	Chief Scientific Officer	$453,980	$200,000	—	$161,735	—	$24,152	$839,867
Sean Moran	Chief Financial Officer	$444,971	$135,403	—	$107,975	—	$28,907	$717,256
Dominic Smethurst	Chief Medical Officer	—	—	—	—	—	—	—

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Yuval Cohen	Chief Executive Officer	$598,071	$277,728	—	$552,172	—	$14,870	$1,442,841
Sean Moran	Chief Financial Officer	$427,933	$132,480	—	$199,563	—	$18,640	$778,616
Rachael Brake	Chief Scientific Officer	$427,779	$108,986	—	$211,573	—	$15,457	$763,795

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Yuval Cohen	Chief Executive Officer	$578,675	$268,320	—	$3,996,599	—	$14,712	$4,858,306
Sean Moran	Chief Financial Officer	$414,054	$128,000	—	$1,284,009	—	$18,854	$1,844,917
Rachael Brake	Chief Scientific Officer	$15,769	—	—	—	—	$38	$15,807

Executive changes

Person	Role	Change	Effective	Filed
Brent Pfeiffenberger	member of the Board	Appointed	2026-05-13	2026-05-14
Dominic Smethurst	Chief Medical Officer	Resigned	2026-06-30	2026-04-07
Alan Holmer	Board of Directors	Retired	2025-12-31	2025-12-18
Ian Hodgson	Chief Operating Officer	Appointed	2025-03-15	2025-03-18
Winston W. Kung	member of the Board	Appointed	2024-08-16	2024-08-20
Avery W. Catlin	Board of Directors	Resigned	2024-08-15	2024-08-20
Yong Ben	director	Appointed	2024-05-16	2024-05-20
Anne Altmeyer	director	Appointed	2024-05-16	2024-05-20
Peter Salzmann	director	Appointed	2024-05-16	2024-05-20
John Jenkins	director	Appointed	2024-05-16	2024-05-20
Rachelle Jacques	director	Appointed	2024-05-16	2024-05-20
Avery W. Catlin	director	Appointed	2024-05-16	2024-05-20
Alan Holmer	director	Appointed	2024-05-16	2024-05-20
Yuval Cohen	director	Appointed	2024-05-16	2024-05-20
Rachael Brake, Ph.D.	Chief Scientific Officer	Resigned	2024-02-19	2024-02-06
Yong Ben	Board of Directors	Appointed	2023-03-01	2023-03-07
Craig Millian	Chief Operating Officer	Resigned	2023-04-14	2023-03-07
Yong Ben, M.D., MBA	member of the Board	Appointed	2023-03-01	2023-03-06
Anne Altmeyer	member of the Board	Appointed	2022-09-20	2022-09-26

Key facts CIK 1595097 CUSIP 21833P301 13F (30d) 102 filings 100 filers Visit website Investor relations